TFE3 and renal cell carcinoma: We have developed a series of TFE3 translocation RCC derived cell lines that represent different TFE3 fusions [2, 22, 23], which were used here in a high-throughput broad spectrum drug screen and to evaluate a GPNMB-targeted antibody-drug conjugate therapy.